Literature DB >> 7849293

ILA, the human 4-1BB homologue, is inducible in lymphoid and other cell lineages.

H Schwarz1, J Valbracht, J Tuckwell, J von Kempis, M Lotz.   

Abstract

We recently identified a gene that is induced by lymphocyte activation (ILA). The sequence of the full-length 1.4-kb cDNA characterized ILA as a new member of the nerve growth factor/tumor necrosis factor (NGF/TNF) receptor family and the human homologue of the murine T-cell-specific receptor 4-1BB. The present study demonstrates ILA mRNA isoforms at 4.4, 4.0, and 1.8 kb in poly-A+ RNA from activated, but not from resting human peripheral blood T lymphocytes. A reverse transcriptase-polymerase chain reaction (RT-PCR) assay was used to study tissue distribution and regulation of ILA expression. The gene was induced in T lymphocytes by phytohemagglutinin (PHA), phorbol myristate acetate (PMA), and antibody to CD3, in B lymphocytes by PMA and antibodies to cell surface Ig, and in blood monocytes by interleukin-1 beta (IL-1 beta), lipopolysaccharide (LPS), and PMA. In T lymphocytes, ILA mRNA was detectable 1.5 hours after stimulation, reached maximal levels at 8 hours, and declined to background levels by 48 hours. Induction of ILA mRNA required protein synthesis and was primarily due to increased transcription. Actinomycin D reduced ILA mRNA levels in activated lymphocytes 50% within 30 minutes, demonstrating a relatively short half-life of this mRNA. Analysis of nonlymphoid cells showed that ILA mRNA was not detectable in resting cells. However, in contrast to the lymphoid-specific expression of the murine 4-1BB gene, ILA was detected in nonlymphoid cells, including epithelial and hepatoma cells after stimulation with IL-1 beta. ILA was not detectable in several brain derived cell lines. The ILA cDNA encodes a 30-kD protein as demonstrated by in vitro translation, and this protein is immunoprecipitated by antisera that were raised against ILA peptides or a glutathione-S-transferase fusion protein. Flow cytometry showed expression of ILA protein on a subset of activated T or B lymphocytes. In conclusion, activation-dependent expression of ILA is found not only in T lymphocytes, but also in B lymphocytes, monocytes, and diverse nonlymphoid cell types.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7849293

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  33 in total

1.  Induction of 4-1BB (CD137) expression by DNA damaging agents in human T lymphocytes.

Authors:  Kwang-Mi Kim; Ho Won Kim; Jae-Ouk Kim; Kyoung-Min Baek; Joong Gon Kim; Chang-Yuil Kang
Journal:  Immunology       Date:  2002-12       Impact factor: 7.397

2.  Study of relieving graft-versus-host disease by blocking CD137-CD137 ligand costimulatory pathway in vitro.

Authors:  Kailin Xu; Chaohong Li; Xiuying Pan; Bing Du
Journal:  Int J Hematol       Date:  2007-07       Impact factor: 2.490

Review 3.  Costimulatory molecules as immunotherapeutic targets in systemic lupus erythematosus.

Authors:  Juergen Foell; Robert S Mittler
Journal:  Springer Semin Immunopathol       Date:  2006-09-02

4.  Cytokine-mediated disruption of lymphocyte trafficking, hemopoiesis, and induction of lymphopenia, anemia, and thrombocytopenia in anti-CD137-treated mice.

Authors:  Liguo Niu; Simona Strahotin; Becker Hewes; Benyue Zhang; Yuanyuan Zhang; David Archer; Trent Spencer; Dirck Dillehay; Byoung Kwon; Lieping Chen; Anthony T Vella; Robert S Mittler
Journal:  J Immunol       Date:  2007-04-01       Impact factor: 5.422

Review 5.  Costimulatory and coinhibitory receptors in anti-tumor immunity.

Authors:  Gregory Driessens; Justin Kline; Thomas F Gajewski
Journal:  Immunol Rev       Date:  2009-05       Impact factor: 12.988

6.  Involvement of CD137 ligand signaling in neural stem cell death.

Authors:  Chang Ho Yun; Hye Myeong Lee; Sang Chul Lee; Byung Sam Kim; Jeong Woo Park; Byung Ju Lee
Journal:  Mol Cells       Date:  2013-08-07       Impact factor: 5.034

7.  Involvement of 4-1BB (CD137)-4-1BBligand interaction in the modulation of CD4 T cell-mediated inflammatory colitis.

Authors:  P Maerten; B S Kwon; C Shen; G De Hertogh; P Cadot; D M A Bullens; L Overbergh; C Mathieu; G Van Assche; K Geboes; P Rutgeerts; J L Ceuppens
Journal:  Clin Exp Immunol       Date:  2006-02       Impact factor: 4.330

8.  Combination therapy with cisplatin and anti-4-1BB: synergistic anticancer effects and amelioration of cisplatin-induced nephrotoxicity.

Authors:  Young H Kim; Beom K Choi; Kwang H Kim; Sang W Kang; Byoung S Kwon
Journal:  Cancer Res       Date:  2008-09-15       Impact factor: 12.701

9.  Regulation of mouse 4-1BB expression: multiple promoter usages and a splice variant.

Authors:  Jung D Kim; Chang H Kim; Byoung S Kwon
Journal:  Mol Cells       Date:  2011-01-11       Impact factor: 5.034

Review 10.  Development of CAR T cells designed to improve antitumor efficacy and safety.

Authors:  Janneke E Jaspers; Renier J Brentjens
Journal:  Pharmacol Ther       Date:  2017-03-22       Impact factor: 12.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.